Merck’s drug prolongs survival in advanced stomach, esophageal cancers in trial

safeimagekit 37ITH3YWMBI7BOQMAQIMBDMV7Y


Merck said on Friday that its experimental cancer drug helped patients with advanced ​stomach and esophageal cancers live longer than ‌standard treatment options in a late-stage trial.

Here are some details:

  • The trial compared the drug, sacituzumab tirumotecan, also known ​as sac-TMT, to physician-selected chemotherapy, including trifluridine-tipiracil, ​irinotecan, paclitaxel or docetaxel
  • The trial enrolled 473 ⁠patients whose cancer could not be removed by ​surgery and whose disease had progressed after at least two earlier ​treatments
  • Sac-TMT is an antibody-drug conjugate, a type of targeted cancer therapy designed to deliver cancer-killing drugs directly to ​tumor cells while minimizing damage to healthy ​tissue
  • Merck said sac-TMT met the trial’s main goal of ‌improving ⁠overall survival but did not disclose detailed data, which it plans to present at a future medical meeting
  • The study, however, did not meet ​its secondary ​goal of ⁠delaying cancer progression, as measured by an independent review. Merck said ​the drug had no new safety ​concerns
  • The ⁠results mark another positive late-stage trial for sac-TMT, which Merck licensed from China’s Kelun-Biotech for markets ⁠outside ​Greater China
  • Merck is currently testing sac-TMT ​for multiple cancers, including lung, breast and gastrointestinal tumors
  • Merck said the overall survival benefit remained consistent across patient subgroups regardless of TROP2 expression levels, while the drug also showed a nominally improved objective response rate that was not formally tested under the study plan
  • TroFuse-015 marks the first time a TROP2-directed antibody-drug conjugate has shown an overall survival benefit in a global Phase 3 trial for advanced gastroesophageal adenocarcinoma, and Merck plans to share the data with health regulators
  • The study is the second positive Phase 3 readout from Merck’s TroFuse program, which spans 18 ongoing late-stage trials enrolling more than 15,000 patients across cancers including endometrial, bladder, cervical, and ovarian tumors

 



Source link

متعلقہ پوسٹ